Entry Point Capital, LLC Olema Pharmaceuticals, Inc. Transaction History
Entry Point Capital, LLC
- $221 Million
- Q4 2024
A detailed history of Entry Point Capital, LLC transactions in Olema Pharmaceuticals, Inc. stock. As of the latest transaction made, Entry Point Capital, LLC holds 69,526 shares of OLMA stock, worth $286,447. This represents 0.18% of its overall portfolio holdings.
Number of Shares
69,526
Previous 34,544
101.27%
Holding current value
$286,447
Previous $412,000
1.7%
% of portfolio
0.18%
Previous 0.24%
Shares
4 transactions
Others Institutions Holding OLMA
# of Institutions
161Shares Held
69.2MCall Options Held
235KPut Options Held
1.3K-
Bain Capital Life Sciences Investors, LLC Boston, MA7.47MShares$30.8 Million11.76% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY7.3MShares$30.1 Million1.62% of portfolio
-
Bvf Inc San Francisco, CA5.72MShares$23.5 Million1.25% of portfolio
-
Black Rock Inc. New York, NY4MShares$16.5 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct3.67MShares$15.1 Million0.05% of portfolio
About Olema Pharmaceuticals, Inc.
- Ticker OLMA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,419,600
- Market Cap $167M
- Description
- Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, local...